Indo Borax acquires 64.26% stake in Kronox Lab Sciences for ₹246.12 crore
Indo Borax & Chemicals Ltd has approved a ₹246.12 crore acquisition of a 64.26% stake in Kronox Lab Sciences Ltd, a specialty fine chemicals manufacturer. The deal, executed at ₹103.22 per share, triggers a mandatory open offer to public shareholders at ₹157.27 per share for up to 25.79% additional stake. Kronox reported FY26 turnover of ₹101.22 crore. The move aims to diversify Indo Borax's portfolio into high-growth specialty chemicals.

*this image is generated using AI for illustrative purposes only.
Indo Borax & Chemicals has moved to expand its portfolio through the acquisition of a controlling stake in specialty chemical manufacturer Kronox Lab Sciences Limited. The company’s Board of Directors, meeting on August 20, 2026, approved the execution of a share purchase agreement to acquire 64.26% of Kronox’s equity shares for an aggregate consideration of ₹246.12 crore.
The transaction involves the purchase of 2.38 crore equity shares from Kronox’s promoters—Ketan Vinodchandra Ramani, Pritesh Vinodchandra Ramani, and Jogindersingh Gianchand Jaswal—at a price of ₹103.22 per share. Zenrock Chemicals Private Limited (ZCPL) is participating in the deal as a person acting in concert with Indo Borax.
Deal Structure and Open Offer
As the acquisition grants Indo Borax control and voting rights exceeding 25% of Kronox’s share capital, the transaction triggers a mandatory open offer under the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (SAST Regulations).
Indo Borax, along with ZCPL, will make an open offer to public shareholders to acquire up to 95.7 lakh equity shares, representing approximately 25.79% of Kronox’s voting share capital. The offer price for the public shareholders is set at ₹157.27 per equity share, determined in accordance with SAST regulations. The entire consideration for both the private agreement and the open offer will be paid in cash via electronic transfer.
| Transaction Component | Details |
|---|---|
| Stake Acquired via SPA | 64.26% (2.38 crore shares) |
| SPA Price Per Share | ₹103.22 |
| Aggregate SPA Consideration | ₹246.12 crore |
| Open Offer Stake | Up to 25.79% (95.7 lakh shares) |
| Open Offer Price Per Share | ₹157.27 |
A footnote in the disclosure notes that while the SPA price is ₹103.22, the effective price inclusive of consultancy fees payable by Kronox to the sellers under transition support arrangements is ₹105.87 per share, as calculated under Regulation 8(7) of the SAST Regulations.
Target Company Profile
Kronox Lab Sciences Limited is engaged in manufacturing high-purity specialty fine chemicals for diversified end-user industries. Based in Vadodara, Gujarat, the target company reported a turnover of ₹101.22 crore for FY26, showing modest growth from ₹100.19 crore in FY25 and ₹89.86 crore in FY24.
Indo Borax stated that the acquisition aligns with its long-term strategy to diversify its portfolio by investing in sectors demonstrating stability and growth potential. The company intends to nurture and expand Kronox’s business to maximize value creation for stakeholders. The acquisition is not classified as a related-party transaction, and no promoter or group company holds an interest in the target entity.
The company expects to complete the acquisition within three months of the public announcement. No governmental or regulatory approvals are required for the deal.
Historical Stock Returns for Indo Borax & Chemicals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +7.20% | +3.57% | -3.32% | +87.75% | +71.18% | +214.47% |
How will Indo Borax leverage Kronox's specialty chemical capabilities to cross-sell products to its existing customer base in the borates and chemicals sector?
What is the projected timeline for realizing operational synergies and cost efficiencies following the integration of Kronox into Indo Borax's portfolio?
Given the significant premium of the open offer price (₹157.27) over the SPA price (₹103.22), how might this valuation benchmark impact future M&A activity in the Indian specialty chemicals space?


































